Perimenopause: How to Prep for Your First Visit

What Perimenopause Actually Is

Perimenopause is the biological transition from your reproductive years to menopause, the point defined as 12 consecutive months without a period. During this phase, ovarian follicle supply declines, estradiol secretion becomes erratic, and follicle-stimulating hormone (FSH) rises in an attempt to recruit remaining follicles. That hormonal volatility, not simply low estrogen, drives most symptoms. The Stages of Reproductive Aging Workshop (STRAW+10) criteria published in Fertility and Sterility formalize perimenopause into early and late stages based on cycle irregularity and FSH thresholds.

STRAW+10 Staging at a Glance

The STRAW+10 framework divides perimenopause into two stages. Early perimenopause (Stage -2) is marked by cycle length variability of 7 or more days from your usual pattern. Late perimenopause (Stage -1) begins when you have 60 or more days between periods. Most women spend roughly 1 to 3 years in Stage -1 before the final menstrual period.

Why the Timing Matters for Treatment

Starting a conversation with your clinician during early perimenopause, rather than waiting until symptoms become severe, gives you more options. The "timing hypothesis," supported by the Women's Health Initiative Memory Study re-analyses and the KRONOS Early Estrogen Prevention Study (KEEPS), suggests that initiating hormone therapy closer to the onset of the transition may carry a more favorable cardiovascular risk profile than starting a decade after menopause. KEEPS (N=727) found no significant change in carotid intima-media thickness with oral conjugated equine estrogen or transdermal estradiol versus placebo over 4 years.

Building Your Symptom Log Before the Appointment

Arriving with documented symptoms rather than a vague recollection changes the quality of your visit significantly. Clinicians use symptom frequency, severity, and timing to stage your transition and to select treatment intensity.

The Four Symptom Domains to Track

Vasomotor symptoms (VMS). Record every hot flash and night sweat: time of day, duration in minutes, and a 0-to-10 severity score. The Menopause Rating Scale (MRS) and the Greene Climacteric Scale are validated tools your clinician may use; pre-filling one saves appointment time. Hot flashes affect up to 80% of women during the menopausal transition and can persist for a median of 7.4 years according to the SWAN Daily Hormone Study.

Sleep and mood. Note nights with disrupted sleep, episodes of anxiety, and any low-mood periods lasting more than two weeks. Perimenopausal women have roughly 2 to 4 times the risk of a major depressive episode compared with premenopausal women, so distinguishing perimenopause-related mood changes from a primary mood disorder matters clinically.

Genitourinary symptoms. Vaginal dryness, dyspareunia, and urinary urgency fall under the umbrella of Genitourinary Syndrome of Menopause (GSM). These symptoms respond poorly to systemic therapy alone and often require local vaginal estrogen added to any systemic regimen.

Cognitive and somatic symptoms. Brain fog, joint aching, and palpitations are reported by a substantial minority of women but are less well-studied. Document their frequency anyway; your clinician may order thyroid function tests to exclude overlap with hypothyroidism.

Your Menstrual Calendar

Bring a minimum of 6 months of cycle data. A simple phone note or free app works. Record the first day of each period, the last day, flow heaviness on a 1-to-5 scale, and any spotting between periods. Intermenstrual spotting in perimenopause usually reflects anovulatory cycles, but it warrants evaluation to exclude endometrial pathology, particularly if you have risk factors for endometrial cancer.

Lab Tests to Expect (and Some to Request)

No single blood test diagnoses perimenopause. The diagnosis is clinical. Labs help exclude mimics and establish cardiovascular and metabolic baselines.

Hormone Panel

Your clinician will likely order FSH, estradiol (E2), and sometimes LH. Because estradiol fluctuates day to day in perimenopause, a single low reading does not confirm the transition; a single high reading does not rule it out. The most useful pattern is a cycle-day-2-to-3 FSH above 10 IU/L on two separate cycles, trending upward. The Endocrine Society Clinical Practice Guideline on Menopause cautions against relying on AMH or inhibin B alone to time the transition in clinical (as opposed to research) settings.

Anti-Mullerian hormone (AMH) testing has become popular in direct-to-consumer settings. AMH does fall progressively toward zero as the follicle pool depletes, but population-based reference ranges for perimenopausal staging are not yet standardized. Request it if your clinician offers it, but do not use a low AMH as sole confirmation.

Metabolic and Cardiovascular Baselines

Order, or ask to have ordered: a fasting lipid panel, fasting glucose or HbA1c, and a complete metabolic panel. LDL-C rises by an average of 10 to 14 mg/dL across the menopausal transition according to the SWAN (Study of Women's Health Across the Nation) cardiovascular substudy. SWAN data (N=3,302 women) showed that the rate of LDL increase accelerated in the 1-year window surrounding the final menstrual period.

Hypertension prevalence also rises steeply at this life stage. If you have not had a blood pressure check in the past year, schedule one before your visit or confirm your clinician will take it in-office.

Bone Density

The 2023 Menopause Society Position Statement recommends considering baseline dual-energy X-ray absorptiometry (DEXA) in women with clinical risk factors for osteoporosis at the time of perimenopause evaluation, not waiting until age 65 as USPSTF suggests for average-risk women. Risk factors include low body weight, smoking history, chronic glucocorticoid use, family history of hip fracture, or prior fragility fracture.

Thyroid and Other Mimics

TSH is worth requesting. Hypothyroidism shares several features with perimenopause: fatigue, weight gain, brain fog, irregular periods, and mood changes. Prolactin and a pregnancy test may also be ordered if amenorrhea is prolonged, given that pregnancy remains possible throughout perimenopause.

Your Medical and Family History: What to Pull Together

Your clinician needs a specific list of personal and family conditions, not a general "I'm pretty healthy."

Personal History Checklist

Compile answers to these before your appointment:

• Age of first period and average cycle length over the past 5 years
• Prior pregnancies, miscarriages, or fertility treatments
• Current contraception method
• Prior or current breast, endometrial, ovarian, or cervical diagnoses
• Personal history of blood clots (deep vein thrombosis or pulmonary embolism)
• Current medications including all supplements, herbal products, and over-the-counter NSAIDs
• Tobacco and alcohol use in standard drink equivalents per week
• BMI or recent weight trend over 2 years

Family History That Changes Treatment Decisions

A first-degree relative with breast cancer before age 50 does not automatically exclude you from hormone therapy, but it shifts the shared-decision-making conversation. Similarly, a first-degree relative with a blood clot may prompt your clinician to favor transdermal rather than oral estrogen, since transdermal routes do not appear to increase venous thromboembolism risk in the same way oral preparations do. A 2015 meta-analysis in BMJ (N=80,396 women) found that oral but not transdermal estrogen was associated with increased VTE risk.

Treatment Options Your Clinician Will Discuss

Perimenopause treatment is not a single prescription. It is a menu matched to your symptom burden, contraceptive needs, cardiovascular profile, and personal preferences.

Low-Dose Combined Oral Contraceptives

If you are still cycling, even irregularly, and need contraception, low-dose combined OCPs (containing 20 mcg ethinyl estradiol) serve two purposes: preventing pregnancy and suppressing the hormonal volatility that drives VMS. They also regulate cycles and may reduce menstrual flow in women with anovulatory heavy bleeding. Contraindications include active smoking plus age over 35, personal VTE history, migraine with aura, or uncontrolled hypertension. If any of these apply, the conversation shifts to progestogen-only pills or non-hormonal methods.

Systemic Hormone Therapy

For women who have completed 12 months without a period, or for perimenopausal women who prefer hormone therapy over OCPs, the standard options are:

• Estrogen-alone therapy: reserved for women after hysterectomy.
• Combined estrogen plus progestogen: required for women with an intact uterus to prevent endometrial hyperplasia. Options include continuous-combined regimens (daily estrogen plus progestogen) or sequential regimens (cycling progestogen for 12 to 14 days per month).

The 2022 Hormone Therapy Position Statement of The Menopause Society states: "For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms." That language represents the current authoritative standard for initiating systemic HT in the appropriate candidate.

Transdermal estradiol patches, gels, and sprays avoid first-pass hepatic metabolism and are preferred in women with hypertriglyceridemia or elevated VTE risk. Micronized progesterone (Prometrium 100 to 200 mg) is the preferred progestogen in most guidelines given its neutral cardiovascular profile compared with synthetic progestins.

Non-Hormonal Options for VMS

Paroxetine mesylate 7.5 mg (Brisdelle) is the only FDA-approved non-hormonal medication for moderate-to-severe VMS. In the key Phase III trial (N=591), paroxetine 7.5 mg reduced hot flash frequency by 33% and severity by 37% versus placebo at 12 weeks. It is the appropriate first-line pharmacologic choice for women who cannot or prefer not to use hormones.

Fezolinetant (Veozah 45 mg daily), a neurokinin 3 receptor antagonist, received FDA approval in May 2023. It targets the KNDy neuron pathway directly responsible for thermoregulatory dysregulation. The SKYLIGHT 1 trial (N=501) showed a 59% reduction in mean daily hot flash frequency at week 12 versus 40% with placebo. Liver function monitoring is required for the first 3 months.

Gabapentin 300 mg three times daily and venlafaxine 75 mg daily are used off-label but have supporting evidence from multiple randomized trials. Bring up these options if cost or formulary coverage is a concern, since fezolinetant carries a significantly higher price point.

Local Vaginal Estrogen for GSM

Systemic therapy does not always resolve GSM. Low-dose local vaginal estrogen (estradiol cream, tablet, or ring) delivers estrogen directly to urogenital tissue with minimal systemic absorption. The ACOG Practice Bulletin on GSM supports vaginal estrogen as safe and effective even in women with a history of hormone-receptor-positive breast cancer when used at low doses and after oncology consultation. Ospemifene 60 mg oral (a selective estrogen receptor modulator) is another non-estrogen option FDA-approved for dyspareunia due to vulvovaginal atrophy.

Questions to Ask Your Clinician

Come with written questions. Clinicians spend more time on documented concerns than on vague verbal ones.

Use this framework to prioritize your questions by category:

Safety and eligibility:

• Am I a candidate for systemic HRT given my personal and family history?
• Should I use transdermal instead of oral estrogen given my cardiovascular risk?
• Do I still need contraception, and can that be combined with symptom treatment?

Efficacy and timeline:

• How long before I notice improvement in hot flashes after starting treatment?
• What is the plan if the first agent does not work after 8 to 12 weeks?
• At what point should we consider dose adjustment versus switching agents?

Monitoring:

• How often will you check my estradiol or FSH once I am on therapy?
• When should I schedule a DEXA scan?
• What symptoms should prompt me to contact you between visits?

Long-term planning:

• How long is it safe or appropriate to stay on hormone therapy?
• What is the tapering plan when I decide to stop?
• Are there lifestyle changes that could reduce my symptom burden without medication?

Lifestyle Inputs That Affect Symptom Severity

Lifestyle changes will not eliminate severe VMS but do reduce their frequency and intensity. Document your current habits before your appointment so your clinician can set realistic expectations.

Exercise and Weight

A 2014 Cochrane review found insufficient evidence that exercise alone significantly reduces hot flash frequency, but exercise consistently improves sleep quality, mood, and cardiometabolic risk markers in perimenopausal women. Weight loss of 10 lbs. Or more in the MENQOL trial was associated with a 33% reduction in hot flash frequency over 6 months.

Dietary Patterns

The MedDiet-Menopause study and a 2023 systematic review in Maturitas found that higher adherence to Mediterranean dietary patterns correlated with lower VMS severity scores. Reducing alcohol intake matters: each daily alcoholic drink raises hot flash frequency by roughly 15% in observational data.

Cognitive Behavioral Therapy

CBT for menopausal symptoms (CBT-MHT), evaluated in the MENOS 1 and MENOS 2 trials, reduced the problem-rating of hot flashes by 44% compared with 8% in wait-list controls. This is a legitimate clinical option to request if medication is not preferred, or to combine with pharmacotherapy.

What to Bring to the Appointment: A Practical Checklist

• Written symptom log covering at least 2 menstrual cycles, with severity scores
• Menstrual calendar for the past 6 months
• Complete medication list including all supplements and OTC products
• Personal medical history summary (prior diagnoses, surgeries, breast biopsies)
• Family history summary for breast cancer, blood clots, heart disease, and osteoporosis
• Most recent labs (within 12 months) if available, including lipids and thyroid
• Insurance card and a list of your pharmacy formulary preferred drugs
• Written list of questions, prioritized by the framework above

Arriving with this material reduces the time your clinician spends gathering basics and increases the time available for shared decision-making about your treatment options. Most perimenopause consultations are scheduled for 20 to 30 minutes. A prepared patient can cover initial staging, safety screening, and a treatment plan in a single visit. An unprepared one often leaves needing a follow-up before anything is prescribed.

The 2023 Menopause Society Position Statement specifies that individualized care, accounting for symptom burden, personal values, cardiovascular risk, and cancer history, is the standard. Your preparation makes that individualization possible at visit one rather than visit three.

Current FDA labeling for all approved HRT products requires the lowest effective dose for the shortest duration consistent with treatment goals. Ask your clinician what the lowest effective starting dose looks like for your specific symptom profile and what the re-evaluation schedule will be, typically every 6 to 12 months once stable.